TY - JOUR T1 - SADL scale as a predictor of mortality in patients with ILD associated with Scleroderma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA2239 VL - 58 IS - suppl 65 SP - PA2239 AU - Virginia Parra León AU - Walther Ivan Girón Matute AU - Fernando Pedraza Serrano AU - Belén Serrano Benavente AU - Christian Reynaldo Castro Riera AU - Luis Puente Maestú Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA2239.abstract N2 - Introduction and Objectives: Interstitial lung disease (ILD) can occur in up to 90% of patients with Scleroderma, being the most frequent all-cause mortality. In recent years, new tools have appeared for these patients, as the SADL mortality prediction model that includes smoking history, age, and percentage of pulmonary diffusion (DLCO). The aim of the study is the application of this scale in our patients.Material and Methods: Observational retrospective study of patients with diagnosis of ILD and Scleroderma from February 2014 to January 2021.Results: We included 23 patients: 87% women, age 54 ± 12.7 years. The baseline characteristics of the population are represented in Table 1. Application of SADL scale and patients’ mortality is shown in table 2.Conclusions: The SADL scale predicts satisfactorily mortality in our patients with Scleroderma and ILD involvement, being an interesting and useful tool to consider in the assessment and therapeutic approach of these patients. View this table:Table 1. Baseline characteristics of the populationView this table:Table 2. SADL scale and mortalityFootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2239.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -